Dr. Gillis’ Wellness Center
Dr. Gillis’ Wellness Center offers Maine weight care with a named physician and walk-in visits. Its wider peptide menu includes investigational claims that deserve careful scrutiny.
Review by Leah Garner, clinical-evidence editor · Updated October 2026
The short version
The local care model and named clinician offer useful accountability, but the retatrutide add-on advertising is a material concern. Discuss approved treatment options before considering the broader peptide menu.
Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
Dr. Gillis’ Wellness Center is a clinic in Oakland, Maine, offering semaglutide and tirzepatide treatment alongside a wider wellness menu. Its FAQ describes walk-in new-patient sessions, medication instruction and the option of office or home administration. The practice also advertises telehealth, which requires confirmation of actual state and prescription eligibility. Other pages list sermorelin, NAD+, glutathione, GHK-Cu and several peptide blends. The existence of a local clinic does not establish that every listed preparation has the same evidence, regulatory status or clinical suitability.
What Dr. Gillis’ Wellness Center prescribes, by goal
Weight
- SemaglutideFDA-approved
Listed by the seller; no price we hold.
- TirzepatideFDA-approved
Listed by the seller; no price we hold.
The clinic names semaglutide and tirzepatide as injectable weight treatments, while separately listing dissolving-tablet options in a pricing PDF. Actual formulation and route should be confirmed for the chosen prescription. A particularly important concern is the current advertising of retatrutide as an add-on to semaglutide or tirzepatide. FDA says retatrutide is not a component of an approved medicine and cannot be used in compounding under federal law. Trial results do not turn that advertised add-on into an approved routine treatment.
Longevity
- NAD+Compounding conditions apply
Listed by the seller; no price we hold.
- GlutathioneCompounding conditions apply
Listed by the seller; no price we hold.
The broader menu includes sermorelin, NAD+ and glutathione with aging, energy or menopause-related claims. The actual route, concentration, indication and supplied period are not equally clear across the public listings. A volume or price alone is insufficient to establish a treatment regimen. The clinician should distinguish established care from uncertain wellness aims before a patient accepts a protocol.
Recovery
- SermorelinCompounding conditions apply
Listed by the seller; no price we hold.
The Wolverine page describes a blend of BPC-157 and TB-500 for tissue repair and recovery, while other material promotes GHK-Cu and a CJC-1295/ipamorelin combination. Those are distinct preparations rather than one interchangeable recovery medicine. Ask what human evidence supports the exact formulation and intended use, along with its regulatory status and monitoring. Statements about being research-supported should not be treated as a guarantee of healing or a reason to combine multiple products.
Sleep
- SermorelinCompounding conditions apply
Listed by the seller; no price we hold.
Who prescribes
A licensed clinician
The clinic names one lead clinician, Brian Gillis, whom its biography describes as an osteopathic physician. It lists specialist certifications and hospital relationships as the practice’s own credentials and experience claims. Those details are more informative than an anonymous doctor reference, but an individual patient should confirm the current professional responsibility for their care. The clinic also names support personnel and a lab technician, whose roles should not be confused with prescribing authority. A familiar community presence is useful context rather than a substitute for assessing the actual treatment proposal.
The FAQ describes complimentary consultations and monthly follow-up check-ins, with walk-in enrollment during published Wednesday hours. It says patients can be shown how to give the first injection in the office, then receive later injections there or administer them at home. That is a concrete difference from a remote storefront, although availability and the selected prescription still need confirmation. The site also advertises nationwide telehealth without publishing a complete verified state-by-state clinical arrangement. Ask how follow-up and urgent concerns are handled when receiving care remotely rather than attending the clinic.
Are labs required?
Not mentioned
The biography names a lab technician and the practice discusses clinical monitoring, but the reviewed public pages do not establish a universal baseline panel or an unlimited included testing allowance. Ask which tests are needed for the specific medicine, when they will be repeated and what they cost. A complimentary consultation does not automatically include outside laboratory work. If a result requires care beyond the program, clarify who will arrange the follow-up rather than assuming a general wellness visit covers every relevant condition.
Ready to start with Dr. Gillis’ Wellness Center?
Prices and plans are set on the seller's own site.
What it claims, and what it cites
The retatrutide offer is a specific reason for caution: the clinic’s medication page promotes a monthly add-on and combination names, while FDA’s current guidance says retatrutide cannot be used in compounding. This is general FDA regulatory guidance applied to a current website claim, not a claim that FDA has issued a warning letter to this clinic. The actual dispensing pharmacy is not identified on the reviewed pages. Obtain the prescription and source details, and do not treat a price list or physician biography as evidence that an investigational medicine is approved.
Other products and treatment claims
- CJC-1295
- On no FDA compounding list. The name does not appear in the 503A bulk drug substances categories (updated May 14, 2026) or in the 503B categories (updated March 21, 2025), so neither a 503A pharmacy nor a 503B outsourcing facility has a listed route to it.
- Ipamorelin
- "Ipamorelin Acetate" is in 503B Category 2, bulk drug substances that raise significant safety risks (list updated March 21, 2025). It is named on no 503A list, so neither an outsourcing facility nor a 503A pharmacy has a listed route to it.
- BPC-157
- On no 503A list (removed from Category 2 in April 2026, never in Category 1). The FDA's compounding advisory committee voted 8–6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
- TB-500
- On no FDA compounding list: absent from the 503A categories (updated May 14, 2026) and the 503B categories (updated March 21, 2025). FDA's compounding advisory committee voted 8-6 (one abstention) in July 2026 to favor listing it; the vote is a recommendation, not binding on the FDA, and pharmacies may not compound it until final rulemaking.
How it bills
The medication page advertises semaglutide from $200 monthly and tirzepatide from $300, while the linked PDFs show dose-tier amounts with a conditional cash discount. Neither the full preparation nor every price’s ordinary repeat period is established. Other peptide figures mix monthly-looking amounts, vial content and administration volumes, which are different purchase descriptions. Consultations and monthly follow-ups are described as complimentary, but testing, delivery and medication refund terms remain incomplete. Obtain one written quote for the actual prescription before comparing a low headline with a different clinic’s complete program.
For and against
- For: A lead clinician and local office are identified
- For: Walk-in care and administration instruction are described
- For: Consultation and monthly follow-up charges are explicit
- Against: Retatrutide add-on advertising conflicts with FDA compounding guidance
- Against: The dispensing pharmacy is not identified publicly
- Against: Price formats and preparation details need reconciliation
- Against: Broad peptide benefit claims require scrutiny
The evidence behind what it sells
- Semaglutide Side Effects: What the Wegovy Trials and Label Recorded
- Glutathione Side Effects: What Injection, IV and Oral Studies Reported
- Sermorelin Side Effects: What the Trials and FDA Record Report
- Tirzepatide Side Effects: What the Zepbound Label and Trials Recorded
- NAD Side Effects: What Injection, IV and Oral Precursor Studies Reported
- Does Sermorelin Work? What the Human Studies Measured
Right for
A patient evaluating conventional weight care locally who will question the wider peptide claims and request a clearly identified prescription.
Look elsewhere if
Someone seeking a routine retail retatrutide add-on or assuming every advertised peptide has an approved indication and established benefit.
Other sellers for weight
Lovely Meds
Also prescribes Semaglutide, Tirzepatide.
Tummala Health
Also prescribes Semaglutide, Tirzepatide.
MEDvidi
Also prescribes Semaglutide, Tirzepatide.
Dr. Gillis’ Wellness Center
Frequently asked questions
- Does a local physician’s menu make retatrutide an approved treatment?
- No. FDA says retatrutide is not a component of an approved drug and cannot be used in compounding.
- Are consultation and follow-up fees published?
- The FAQ describes consultations and monthly follow-up appointments as complimentary, without establishing all other charges.
- Is the dispensing pharmacy named?
- Not in the public pages reviewed. Confirm the actual prescription source and preparation before accepting treatment.
Sources
- Care and treatment: Current weight-care services and injection scope
- Care and treatment: Medication amounts and investigational add-on advertising
- Care and treatment: Walk-in, clinical follow-up and fulfillment FAQ
- Care and treatment: Named physician biography and scope
- Care and treatment: Current Wolverine blend ingredients
- Care and treatment: GHK-Cu injection program
- Care and treatment: Published clinic service pricing
- Care and treatment: FDA current guidance on unapproved GLP-1 products and retatrutide
- Care: currently linked dose-tier pricing PDF 1
- Care: currently linked dose-tier pricing PDF 2
See what Dr. Gillis’ Wellness Center prescribes today
Dr. Gillis’ Wellness Center sets its own prices, plans and the states it serves. Check them before you start.